Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,816 across all filing types
Latest filing 2024-03-04 Transaction in Own Shar…
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Transactions in connection with share buy-back program
Transaction in Own Shares Classification · 1% confidence The document is a company announcement from Genmab detailing specific transactions executed under a share buy-back program. It provides a table of daily share repurchases, the total number of shares acquired, and the impact on treasury shares. This aligns perfectly with the definition of 'Transaction in Own Shares' (POS), which covers reports of a company buying back its own shares.
2024-03-04 English
Transactions in connection with share buy-back program
Transaction in Own Shares Classification · 1% confidence The document is a company announcement detailing specific transactions executed under a share buy-back program. It provides a table of daily share repurchases, the total value, and the impact on treasury shares. This aligns perfectly with the definition of 'Transaction in Own Shares' (POS), which covers reports of a company buying back its own shares.
2024-03-04 English
6-K
Foreign Filer Report
2024-03-02 English
Director's Dealing 2024
Director's Dealing Classification · 1% confidence The document is titled "Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons" and explicitly references compliance with Article 19 of Regulation No. 596/2014 on Market Abuse. It details specific acquisitions of shares by named managerial employees (CEO, CFO, Board Members) due to vesting of restricted stock units. This content directly relates to insider trading disclosures and personal share transactions by directors and executives. This matches the definition for Director's Dealing (DIRS). Although it is a 'Company Announcement' and includes an attachment, the core subject matter is the required disclosure of insider transactions, making DIRS more specific than a general RPA or RNS.
2024-03-02 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing Classification · 1% confidence The document is a formal disclosure of transactions in company shares by managerial employees (CEO, CFO, and Board members) due to the vesting of restricted stock units. This falls under the category of 'Director's Dealing' (DIRS), which covers insider trades and transactions by persons discharging managerial responsibilities as required by market abuse regulations.
2024-03-02 English
Regulatory Filings 2024
Regulatory Filings
2024-03-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.